Skip to main content
Log in

Pain palliation and nuclear medicine

  • Editorial
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM (1988) Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549–567

    PubMed  Google Scholar 

  • Erf LA, Lawrence JH (1941) Phosphorous metabolism in neoplastic tissues. Proc Soc Exp Biol Med 48:694–695

    Google Scholar 

  • Firusian N, Mellin P, Schmidt CG (1976) Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 118:764–768

    Google Scholar 

  • Holmes RA (1992) [135Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med 22:41–45

    PubMed  Google Scholar 

  • Kaplan E, Fels IG, Kotiowski BR, Greco J, Walsh WS (1960) Therapy of carcinoma of the prostate metastatic to bone with 32p labelled condensed phosphate. J Nucl Med 1:1–13

    Google Scholar 

  • Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, MacLeod PM, Porter AT, Zivanovic MA (1991) A prospective, randomized double blind cross over study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27:954–958

    PubMed  Google Scholar 

  • Lewington VJ, Boyer PJ, Dearnaly DP, Kirk D, Quilty PM, Yardley J, Zivanovic MA (1992)89Sr — an effective alernative to radiotherapy for prostatic metastases. Nucl Med Commun 13:211–212

    Google Scholar 

  • Mauch Pm, Drew MA (1985) Treatment of metastable cancer to bone. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice. Lippincott, Philadelphia, pp 2132–2141

    Google Scholar 

  • Maxon HR, Deutsch EA, Thomms SR (1988) Re-186(Sr)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 166:501–507

    PubMed  Google Scholar 

  • Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ, Schneider HJ (1991) Re-186(Sn) HEDP for treatment of painful osseous metastases: result of a double blind crossover comparison with placebo. J Nucl Med 32:1877–1881

    PubMed  Google Scholar 

  • McEwan AJ, Porter AT, McGowan D, Amyotte G (1992) Adjuvant strontium-89 in prostate cancer: First report of the transCanada collaborative study. Eur J Nucl Med 19:608

    Google Scholar 

  • Montebello JF and Harston-Eaton M (1989) The palliation of osseous metastases with32P or89Sr compared with external beam and hemibody radiotherapy: an historical perspective. Cancer Investigation 7:139–160

    PubMed  Google Scholar 

  • Robinson RG, Preston DF, Spicer JA, Baxter KG (1992) Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 22:28–32

    PubMed  Google Scholar 

  • Silberstein EB, Elgazzar AH, Kapilivsky A (1992) Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med 22:17–27

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McEwan, A.J.B. Pain palliation and nuclear medicine. Eur J Nucl Med 20, 1–3 (1993). https://doi.org/10.1007/BF02261237

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02261237

Navigation